The NHS Standard for Buying Medical Tech Never Checks Results

← Back · ACT II · Chapter 7: Value Is Not Promised; It Is Proven

On 11 June 2026 the Department of Health and Social Care published its value based procurement national standard guidance for medical technology, developed with NHS England and NHS Supply Chain. It tells NHS buyers how to judge value when they buy medical devices. Five value domains, a combined minimum weighting of sixty percent, and whole life cost capped at forty. For a buying system that has defaulted to the lowest compliant price for decades, that is a real change, and it should be said first.

Read the document end to end and something is missing. The word verify is not in it. Neither is verification, nor verified, nor the phrase after award. What the guidance covers, in its own words, is “the quality assessment stage in the procurement process (that is, in relation to the evaluation of tenders).” It states the boundary plainly: “This guidance does not cover the end-to-end procurement process for medical devices.”

So the national standard for value is a standard for scoring a tender. Everything it treats as value is a claim about what a device will do, supplied by the company selling it, and assessed before a single patient has used it.

What The Standard Makes Mandatory

The five domains are social value, efficiency, patient and staff, supply chain, and purpose, with whole life cost alongside them. Buyers pick the domains and questions that fit what they are buying. The word must appears twice in the whole document, and both times it is doing arithmetic: “Combined, the 5 value domains should have a minimum sum weighting of 60%, 10% of which must be allocated to the social value domain.”

Everything that happens after the contract is signed is written in should, may, consider, and where appropriate. In government guidance that difference is not a matter of tone, because must binds a buyer and should does not.

Who Produces The Evidence

There is a measurement question, and it is the strongest thing in the document. Question 2.4 asks the bidder to “Detail how you will measure and monitor the delivery of claimed benefits and/or commitments arising through the delivery of the contract.” It is a tender question, scored at evaluation, so a supplier earns points for describing a measurement plan well. Nothing requires the plan to be run once the contract starts, and nothing asks the buyer to go back and look.

The validation basis for that same question puts the measuring in the supplier’s hands: “The supplier to set out measurement methodology including detail of any access to information or data which the buyer will need to provide to the supplier to enable such measurement and monitoring.” The guidance sees the problem and answers it by pointing at third-party data: “To support impartiality, this should use existing data repositories where possible”. That settles where the numbers come from, and still leaves the supplier measuring its own delivery.

Then there is the glossary. It defines enable as “To enable the buyer to achieve. This does not require that the buyer takes up the relevant opportunity.” Most of the scored questions ask a supplier how it will enable the buyer to do something. Under that definition a supplier can score well on every domain, the benefit can still never appear in the hospital, and none of that counts as a shortfall.

What Happens When The Benefit Does Not Arrive

One sentence in the guidance takes this on: “When monitored data does not meet the promised outcomes, clear mechanisms should exist to determine the extent to which the deliverable is accountable.” Look for who is told to build those mechanisms. There is nobody in the sentence. The passage then lists reasons a shortfall may not be the supplier’s doing, patient demographics, physician workflows, local care pathways, and closes on fairness to buyers and suppliers.

The document contains no remedy: no price adjustment, no service credit, no termination, and no note kept against a supplier that did not deliver what it promised.

The Annex, Read Fairly

Annex B does carry a section headed post-award measurement and learning, and it says the right things. Buyers should have “monitored delivery regularly and address gaps between promised and realised benefits in a transparent way.” That is the instruction the rest of the guidance does not give. It carries no weighting, no scoring method, no template and no required output, and the annex introduces itself as “an indicative aide rather than an exhaustive list.” Four bullets sit there at the end, after pages of weighted and scored machinery built for the decision.

The Same Government Already Built The Other Half

The Procurement Act 2023 requires a contracting authority, before entering a public contract worth more than five million pounds, to set at least three key performance indicators and publish them, and then to publish an assessment of how the supplier performed against them at least once every twelve months. The Act lets an authority skip the indicators where it decides the supplier’s performance could not appropriately be assessed that way, and it leaves frameworks, private utility contracts, concession contracts and light touch contracts outside the duty to set them at all. That carve-out matters here, because a large share of NHS device buying runs through frameworks. NHS trusts are contracting authorities, and the assessment duty has applied since 1 January 2026 to contracts awarded under the Act.

So one part of government requires a published verdict on supplier performance during delivery, and another part writes the national definition of value without reaching for it. The domains a buyer weights at award and the indicators that same buyer publishes a year later are two separate lists, and nothing in either instrument connects them. In central government the two lists have already been joined, by a procurement policy note that fixes a minimum weight at award and directs that the same commitment be monitored through the indicators the buyer publishes, as policy direction rather than statute. The NHS guidance has not done the same.

What A Buyer Can Do Before The Guidance Catches Up

Take each domain that carried weight in the award and turn it into a named measure, with a baseline agreed before the device arrives, a date when it will be read, and a person who reads it. Where the Act already makes you publish indicators, make them the same measures the tender was scored on rather than a second set invented later. Where the contract sits outside that duty, set them anyway. Write into the contract what happens if the number does not move, because the guidance will not do it for you.

The scoring was never the difficult part. Until the guidance is extended past the award, the part that establishes whether the value arrived belongs to the buyer, and it has to be written down before the contract is signed.

References: Department of Health and Social Care, Value based procurement national standard guidance for medical technology, GOV.UK, published 11 June 2026. Procurement Act 2023, section 52, including subsection (6), and section 71, legislation.gov.uk; the Procurement Act 2023 (Commencement No. 4) Regulations 2025, regulation 2(1)(b), bring section 71 into force on 1 January 2026 for contracts awarded under the Act. Sources re-read 25 September 2026.

Keep reading: ACT II · Chapter 7: Value Is Not Promised; It Is Proven